ALLG HD12: This study aims to assess the effect of immunotherapy in combination with chemotherapy for the treatment of elderly patients with early- or advanced-stage Hodgkin LymphomaAn ALLG phase II study of CHOP And Tislelizumab in elderly patients with Hodgkin Lymphoma

Exclusion

1. Central nervous system involvement
2. Requirement of urgent treatment due to life threatening complications of the disease.
3. Immunosuppressive therapy within the last 2 months, apart from inhaled or topical corticosteroids or systemic corticosteroids at low doses (equal to or greater than 10mg prednisone per day or equivalent)
4. Has active auto-immune disease that has required systemic treatment in the prior 2 years with immunosuppressive agents. Replacement therapy such as thyroxine, insulin or physiological steroid replacement for adrenal or pituitary insufficiency is not considered a form of systemic therapy, and hence patients on these therapies are allowed.
5. History of inflammatory bowel disease or pneumonitis
6. Prior treatments with chemotherapy or radiotherapy within 15 days prior to registration.
7. Prior anthracycline use equivalent to greater than 150mg/m2 of doxorubicin.
8. History of malignancy during the past 2 years except for locally curable cancers, that have had curative surgical treatment. Examples are:
-Treated carcinoma in situ at any site (e.g. cervix, breast)
Adequately treated non melanoma skin cancer
-Superficial bladder cancer, adequately treated with surgical/cauterisation. (BCG treatment is excluded)
-Untreated chronic lymphocytic leukaemia with a less than 50% rise in the lymphocyte count in the preceding 6 months
-Low risk early-stage prostate adenocarcinoma (Gleason score equal to or less than 6).
-Pre-malignant lesions (e.g. monoclonal gammopathy of uncertain significance, monoclonal B cell lymphocytosis) are allowed.
9. Uncontrolled active infection (defined as an infection that requires intravenous anti-microbial treatment,) at the time of first dose of therapy.